Drug and Drug candidate building block analysis

Journal of Chemical Information and Modeling

Volumn 50, Issue 1, 2010, Pages 55-67

  Wang, Junmei ^a   Hou, Tingjun ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b SOOCHOW UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MOLECULES; SCAFFOLDS;

BUILDING BLOCKES; CLINICAL TRIAL; DRUG CANDIDATES; DRUG MOLECULES; FORCE-APPROACH; PHYSIO-CHEMICAL PROPERTIES; SCREENING COMPOUNDS; STRUCTURAL FEATURE;

BUILDINGS;

DRUG;

ALGORITHM; ARTICLE; CHEMISTRY; DRUG DEVELOPMENT; FACTUAL DATABASE; METHODOLOGY;

ALGORITHMS; DATABASES, FACTUAL; DRUG DISCOVERY; PHARMACEUTICAL PREPARATIONS;

EID: 75749105013     PISSN: 15499596     EISSN: 1549960X     Source Type: Journal    
DOI: 10.1021/ci900398f     Document Type: Article

References (33)

1. Dobson, C. M. Chemical space and biology. Nature 2004, 432, 824828.
2. Blum, L. C; Reymond, J.-L. 970 million druglike small molecules for virtual screening in the chemical universe database GDB-13. J. Am. Chem. Soc. 2009, 131, 8732-8733.
3. Drugs@FDA. http://www.accessdata.fda.gov/Scripts/cder/DrugsatFDA/ (accessed Dec 2009).
4. Kola,L;Landis,J.Canthepharmaceuticalindustryreduceattritionrates.Nat.Rev. DrugDiscovery2004,3,711-715.(Pubitemid39173511)
5. Leeson, P. D.; Springthorpe, B. The influence of drug-like concepts on decision-making in medicinal chemistry. Nat. Rev. Drug Discovery 2007, 6, 881-890. (Pubitemid 350042396)
6. Muegge, I. Selection criteria for drug-like compounds. Med. Res. Rev. 2003, 23, 302-321.
7. Clark, D. E.; Pickett, S. D. Computational methods for the prediction of 'drug-likeness'. Drug Discovery Today 2000, 5, 49-58.
8. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev. 1997, 23, 3-25.
9. Moriguchi, L; Hirono, S.; Liu, Q.; Nakagome, L; Matsushita, Y. Simple method of calculating octanol water partition-coefficient. Chem. Pharm. Bull. 1992, 40, 127-130.
10. Wenlock, M. C; Austin, R. P.; Barton, P.; Davis, A. M.; Leeson, P. D. A comparison of physiochemical property profiles of development and marketed oral drugs. J. Med. Chem. 2003, 46, 1250-1256.
11. Vieth, M.; Sutherland, J. J. Dependence of molecular properties on proteomic family for marketed oral drugs. J. Med. Chem. 2006, 49, 3451-3453.
12. Wang, J. M.; Krudy, G.; Xie, X. Q.; Wu, C. D.; Holland, G. Genetic algorithm-optimized QSPR models for bioavailability, protein binding, and urinary excretion. J. Chem. Inf. Model. 2006, 46, 2674-2683. (Pubitemid 46008136)
13. Wang, J. M.; Krudy, G.; Hou, T. J.; Zhang, W.; Holland, G.; Xu, X. J. Development of reliable aqueous solubility models and their application in druglike analysis. J. Chem. Inf. Model. 2007, 47, 1395-1404.
14. Wang, J.; Hou, T. Recent Advances on in silico ADME Modeling. Ann. Rep. Comput. Chem. 2009, 5, 101-127.
15. Bemis, G. W.; Murcko, M. A. The properties of known drugs. 1. Molecular frameworks. J. Med. Chem. 1996, 39, 2887-2893.
16. Bemis, G. W.; Murcko, M. A. Properties of known drugs. 2. Side chains. J. Med. Chem. 1999, 42, 5095-5099.
17. Wang, J. S.; Lai, L. H.; Tang, Y. Q. Structural features of toxic chemicals for specific toxicity. J. Chem. Inf. Comput. Sci. 1999, 39, 1173-1189.
18. Lee, M. L.; Schneider, G. Scaffold architecture and pharmacophore properties of natural products and trade drugs: Application in the design of natural product-based combinatorial libraries. J. Comb. Chem. 2001, 3, 284-289. (Pubitemid 33616450)
19. Siegel, M. G.; Vieth, M. Drugs in other drugs: a new look at drugs as fragments. Drug Discovery Today 2007, 12, 71-79. (Pubitemid 46014488)
20. Sutherland, J. J.; Higgs, R. E.; Watson, L; Vieth, M. Chemical fragments as foundations for understanding target space and activity prediction. /. Med. Chem. 2008, 51, 2689-2700. (Pubitemid 351620791)
21. Grabowski, K.; Schneider, G. Propertises and Architecture of Drugs and Natural Products Revisited. Curr. Chem. Biol. 2007, 1, 115-127.
22. Wishart, D. S.; Knox, C; Guo, A. C; Cheng, D.; Shrivastava, S.; Tzur, D.; Gautam, B.; Hassanali, M. DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008, 36, D901-D906.
23. Gao, Z. T.; Li, H. L.; Zhang, H. L.; Liu, X. F.; Kang, L.; Luo, X. M.; Zhu, W. L.; Chen, K. X.; Wang, X. C; Jiang, H. L. PDTD: a web- accessible protein database for drug target identification. BMC Bioinfi 2008, 9.
24. The Derwent World Drug Index, version 3; Derwent Publications, Ltd: London, 1999.
25. Hou, T. J.; Wang, J. M.; Zhang, W.; Xu, X. J. ADME evaluation in drug discovery. 6. Can oral bioavailability in humans be effectively predicted by simple molecular property-based rules. J. Chem. Inf. Model. 2007, 47, 460-463.
26. Hou, T. J.; Wang, J. M.; Zhang, W.; Xu, X. J. ADME evaluation in drug discovery. 7. Prediction of oral absorption by correlation and classification. J. Chem. Inf. Model. 2007, 47, 208-218. (Pubitemid 46225576)
27. Irwin, J. J.; Shoichet, B. K. ZINC - A free database of commercially available compounds for virtual screening. J. Chem. Inf. Model. 2005, 45, 177-182.
28. Clark, R. D.; Langton, W. J. Balancing representativeness against diversity using optimizable K-dissimilarity and hierarchical clustering. J. Chem. Inf. Comput. Sci. 1998, 38, 1079-1086.
29. Stahl, M.; Guba, W.; Kansy, M. Integrating molecular design resources within modern drug discovery research: the Roche experience. Drug Discovery Today 2006, 11, 326-333.
30. Zhao, H. Y. Scaffold selection and scaffold hopping in lead generation: a medicinal chemistry perspective. Drug Discovery Today 2007, 12, 149-155.
31. Zartler, E. R.; Shapiro, M. J. Fragonomics: fragment-based drug discovery. Curr. Opin. Chem. Biol. 2005, 9, 366-370.
32. Erlanson, D. A.; McDowell, R. S.; O'Brien, T. Fragment-based drug discovery. J. Med. Chem. 2004, 47, 3463-3482.
33. Rees, D. C; Congreve, M.; Murray, C. W.; Carr, R. Fragment-based lead discovery. Nat. Rev. Drug Discovery 2004, 3, 660-672.